TIMING OF EU5 & US ORPHAN DRUG APPROVALS AND PRMA BETWEEN 2009 AND 2013

被引：0
作者：
Mycka, J. [1 ]
Dellamano, R. [2 ]
Lobb, W. [1 ]
Dalal, N. [1 ]
Pereira, E. [1 ]
Dellamano, L. [2 ]
Sagaydachnaya, O. [1 ]
Lue, J. [1 ]
机构：
[1] Med Mkt Econ LLC MME, Montclair, NJ USA
[2] ValueVector, Milan, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.1775
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY77
引用
收藏
页码：A305 / A305
页数：1
相关论文
共 50 条
  • [21] MARKET ACCESS OF CELLULAR AND GENE THERAPY PRODUCTS IN THE US AND EU5
    Mycka, J.
    Dellamano, R.
    Lobb, W.
    Pereira, E.
    Dalal, N.
    Dellamano, L.
    Liguori, G.
    Poliakoff, K.
    VALUE IN HEALTH, 2017, 20 (05) : A18 - A18
  • [22] MARKET ACCESS TRENDS ACROSS THE EU5: 2009 TO 2016-AN UPDATE
    Mycka, J.
    Dellamano, R.
    Lobb, W.
    Dalal, N.
    Dellamano, L.
    Pereira, M.
    Mora, M.
    VALUE IN HEALTH, 2017, 20 (09) : A677 - A677
  • [23] An Overview and Analysis Regarding the Use of Adjudication Methods in EU and US Drug Approvals
    Krumholz-Bahner, Stephanie
    Medic, Rer
    Garibbo, Mimmo
    Getz, Kenneth A.
    Widler, Beat E.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (06) : 831 - 839
  • [24] THE PROMISING FUTURE OF DIGITAL HEALTH: A ROAD TO REIMBURSEMENT IN US & EU5 MARKETS?
    Sheppard, H.
    VALUE IN HEALTH, 2023, 26 (12) : S432 - S432
  • [25] EPIDEMIOLOGY OF MYASTHENIA GRAVIS IN US, EU5 AND JAPAN: A SYSTEMATIC LITERATURE REVIEW
    Kumar, S.
    Mishra, A.
    Dhami, Y.
    Sharma, S.
    Bergemann, R.
    VALUE IN HEALTH, 2020, 23 : S336 - S336
  • [26] An Overview and Analysis Regarding the Use of Adjudication Methods in EU and US Drug Approvals
    Stephanie Krumholz-Bahner
    Mimmo Garibbo
    Kenneth A. Getz
    Beat E. Widler
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 831 - 839
  • [27] Describing real-world pediatric psoriasis patients in the US and EU5
    Chapman-Rothe, Nadine
    Richardson, Craig
    Scott, Amie
    Tian, Haijun
    Van der Meulen, Fetske
    Bachhuber, Teresa
    Lobosco, Steve
    Lucas, James
    Meakin, Sophie
    Hetherington, James
    Piercy, James
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB123 - AB123
  • [28] COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5
    Annunziata, K.
    Sternbach, N.
    Carpinella, C. M.
    Chapnick, J.
    Patel, P.
    McDonald, M.
    McElwee, N.
    VALUE IN HEALTH, 2018, 21 : S140 - S140
  • [29] DIFFERENCE BETWEEN UNITED STATES AND EU AUTHORISATION TIMELINES AND TIME TO REIMBURSEMENT IN THE EU5
    Sun, D.
    Beckerman, R.
    VALUE IN HEALTH, 2014, 17 (03) : A17 - A17
  • [30] DELAY BETWEEN HIV DIAGNOSIS AND TREATMENT INITIATION ACROSS THE EU5
    Deemer, J.
    Bradshaw, K.
    Yaacob, N. B.
    VALUE IN HEALTH, 2018, 21 : S234 - S234
12345